American Intellect


U.S. News

Pharmaceutical Company, Novartis, Flagged For Safety Issues on Cancer Tumors Caused By Its Gene-Therapy Product

Started by American Intellect Newsdesk

Zolgensma is an Adeno-Associated Virus (AAV) vector-based DNA gene replacement therapy: it works by delivering a permanent, double-stranded DNA copy of a human gene into a child's cells to replace a missing or defective gene. The risk of insertional oncogenesis being investigated occurs precisely because this DNA payload can physically enter the cell nucleus and accidentally integrate into the host's chromosomes. Out of more than 6,000 children treated globally over the years, a tiny cluster of 9 tumor cases emerged, prompting the FDA to issue a communication to clinicians to ensure patients are appropriately monitored. The therapy was originally developed by a clinical-stage biotechnology company called AveXis, which Novartis acquired in 2018 for $8.7 billion. Following the acquisition, the product was brought to market and is officially produced and distributed by Novartis Gene Therapies. The Gates Foundation granted $20 million to Novartis for sickle cell research and $5 million for malaria tracking in developing countries, a $75 million anchor commitment to the $300 million fund for Adjuvant Capital partnership Gates has with Novartis, while remaining $225 million was filled by a collaborative group of development finance institutions, foundations, and major pharmaceutical corporations, including Novartis and Merck & Co.

Read the discussion


Send this to someone

Email X Facebook Reddit


A civic square for verified Americans, open to the nations of the world, its leaders & ambassadors. Reading is open to everybody. Posting, replying and voting are for members.

Join American Intellect Sign in